Skip to main content
NCBI home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1996 Oct;9(4):512–531. doi: 10.1128/cmr.9.4.512

Carrier effects on biological activity of amphotericin B.

J Brajtburg 1, J Bolard 1
PMCID: PMC172908  PMID: 8894350

Abstract

Amphotericin B (AmB), the drug of choice for the treatment of most systemic fungal infections, is marketed under the trademark Fungizone, as an AmB-deoxycholate complex suitable for intravenous administration. The association between AmB and deoxycholate is relatively weak; therefore, dissociation occurs in the blood. The drug itself interacts with both mammalian and fungal cell membranes to damage cells, but the greater susceptibility of fungal cells to its effects forms the basis for its clinical usefulness. The ability of the drug to form stable complexes with lipids has allowed the development of new formulations of AmB based on this property. Several lipid-based formulations of the drug which are more selective in damaging fungal or parasitic cells than mammalian cells and some of which also have a better therapeutic index than Fungizone have been developed. In vitro investigations have led to the conclusion that the increase in selectivity observed is due to the selective transfer of AmB from lipid complexes to fungal cells or to the higher thermodynamic stability of lipid formulations. Association with lipids modulates AmB binding to lipoproteins in vivo, thus influencing tissue distribution and toxicity. For example, lipid complexes of AmB can be internalized by macrophages, and the macrophages then serve as a reservoir for the drug. Furthermore, stable AmB-lipid complexes are much less toxic to the host than Fungizone and can therefore be administered in higher doses. Experimentally, the efficacy of AmB-lipid formulations compared with Fungizone depends on the animal model used. Improved therapeutic indices for AmB-lipid formations have been demonstrated in clinical trials, but the definitive trials leading to the selection of an optimal formulation and therapeutic regimen have not been done.

Full Text

The Full Text of this article is available as a PDF (422.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler-Moore J. P., Chiang S. M., Satorius A., Guerra D., McAndrews B., McManus E. J., Proffitt R. T. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother. 1991 Oct;28 (Suppl B):63–71. doi: 10.1093/jac/28.suppl_b.63. [DOI] [PubMed] [Google Scholar]
  2. Ahmad I., Sarkar A. K., Bachhawat B. K. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B. Indian J Biochem Biophys. 1989 Dec;26(6):351–356. [PubMed] [Google Scholar]
  3. Ahrens J., Graybill J. R., Craven P. C., Taylor R. L. Treatment of experimental murine candidiasis with liposome-associated amphotericin B. Sabouraudia. 1984;22(2):163–166. doi: 10.1080/00362178485380251. [DOI] [PubMed] [Google Scholar]
  4. Allen S. D., Sorensen K. N., Nejdl M. J., Durrant C., Proffit R. T. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother. 1994 Dec;34(6):1001–1013. doi: 10.1093/jac/34.6.1001. [DOI] [PubMed] [Google Scholar]
  5. Allende M. C., Lee J. W., Francis P., Garrett K., Dollenberg H., Berenguer J., Lyman C. A., Pizzo P. A., Walsh T. J. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother. 1994 Mar;38(3):518–522. doi: 10.1128/aac.38.3.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Allendoerfer R., Yates R. R., Sun S. H., Graybill J. R. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol. 1992;30(5):377–384. doi: 10.1080/02681219280000491. [DOI] [PubMed] [Google Scholar]
  7. Amantea M. A., Bowden R. A., Forrest A., Working P. K., Newman M. S., Mamelok R. D. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother. 1995 Sep;39(9):2042–2047. doi: 10.1128/aac.39.9.2042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Anaissie E., Paetznick V., Proffitt R., Adler-Moore J., Bodey G. P. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis. 1991 Aug;10(8):665–668. doi: 10.1007/BF01975823. [DOI] [PubMed] [Google Scholar]
  9. Apperley J. F. Umbilical cord blood progenitor cell transplantation. The International Conference Workshop on Cord Blood Transplantation, Indianapolis, November 1993. Bone Marrow Transplant. 1994 Aug;14(2):187–196. [PubMed] [Google Scholar]
  10. Baily G. G., Nandy A. Visceral leishmaniasis: more prevalent and more problematic. J Infect. 1994 Nov;29(3):241–247. doi: 10.1016/s0163-4453(94)91059-6. [DOI] [PubMed] [Google Scholar]
  11. Bangham A. D. Liposomes: realizing their promise. Hosp Pract (Off Ed) 1992 Dec 15;27(12):51-6, 61-2. doi: 10.1080/21548331.1992.11705537. [DOI] [PubMed] [Google Scholar]
  12. Barwicz J., Christian S., Gruda I. Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother. 1992 Oct;36(10):2310–2315. doi: 10.1128/aac.36.10.2310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Barwicz J., Gareau R., Audet A., Morisset A., Villiard J., Gruda I. Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems. Biochem Biophys Res Commun. 1991 Dec 16;181(2):722–728. doi: 10.1016/0006-291x(91)91250-g. [DOI] [PubMed] [Google Scholar]
  14. Belay T., Hospenthal D. R., Rogers A. L., Patterson M. J. Treatment of systemic candidiasis in a neutropenic murine model using immunoglobulin G bearing liposomal amphotericin B. Mycopathologia. 1993 Jul;123(1):9–17. doi: 10.1007/BF01103483. [DOI] [PubMed] [Google Scholar]
  15. Berman J. D., Hanson W. L., Chapman W. L., Alving C. R., Lopez-Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother. 1986 Dec;30(6):847–851. doi: 10.1128/aac.30.6.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Berman J. D., Ksionski G., Chapman W. L., Waits V. B., Hanson W. L. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob Agents Chemother. 1992 Sep;36(9):1978–1980. doi: 10.1128/aac.36.9.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Boggs J. M., Chang N. H., Goundalkar A. Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen. Antimicrob Agents Chemother. 1991 May;35(5):879–885. doi: 10.1128/aac.35.5.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Bolard J., Cheron M. Association of the polyene antibiotic amphotericin B with phospholipid vesicles: perturbation by temperature changes. Can J Biochem. 1982 Aug;60(8):782–789. doi: 10.1139/o82-097. [DOI] [PubMed] [Google Scholar]
  19. Bolard J., Cheron M., Mazerski J. Effect of surface curvature on the interaction of single lamellar phospholipid vesicles with aromatic and nonaromatic heptaene antibiotics (vacidin A and amphotericin B). Biochem Pharmacol. 1984 Nov 15;33(22):3675–3680. doi: 10.1016/0006-2952(84)90156-4. [DOI] [PubMed] [Google Scholar]
  20. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta. 1986 Dec 22;864(3-4):257–304. doi: 10.1016/0304-4157(86)90002-x. [DOI] [PubMed] [Google Scholar]
  21. Bolard J., Legrand P., Heitz F., Cybulska B. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry. 1991 Jun 11;30(23):5707–5715. doi: 10.1021/bi00237a011. [DOI] [PubMed] [Google Scholar]
  22. Brajtburg J., Elberg S., Bolard J., Kobayashi G. S., Levy R. A., Ostlund R. E., Jr, Schlessinger D., Medoff G. Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis. 1984 Jun;149(6):986–997. doi: 10.1093/infdis/149.6.986. [DOI] [PubMed] [Google Scholar]
  23. Brajtburg J., Elberg S., Kobayashi G. S., Bolard J. Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses. Antimicrob Agents Chemother. 1994 Feb;38(2):300–306. doi: 10.1128/aac.38.2.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Brajtburg J., Elberg S., Kobayashi G. S., Medoff G. Inhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micelles. Antimicrob Agents Chemother. 1990 Dec;34(12):2415–2416. doi: 10.1128/aac.34.12.2415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Brajtburg J., Elberg S., Schwartz D. R., Vertut-Croquin A., Schlessinger D., Kobayashi G. S., Medoff G. Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob Agents Chemother. 1985 Feb;27(2):172–176. doi: 10.1128/aac.27.2.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Brajtburg J., Elberg S., Travis S. J., Kobayashi G. S. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Antimicrob Agents Chemother. 1994 Feb;38(2):294–299. doi: 10.1128/aac.38.2.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Brajtburg J., Gruda I., Daigle I., Medoff G. Concentration dependent dual effect of the monolauryl ester of sucrose on the antifungal activity and absorption spectra of amphotericin B (Fungizone). Biochim Biophys Acta. 1989 Nov 3;985(3):307–312. doi: 10.1016/0005-2736(89)90417-3. [DOI] [PubMed] [Google Scholar]
  28. Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 1990 Feb;34(2):183–188. doi: 10.1128/aac.34.2.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Caillot D., Casasnovas O., Solary E., Chavanet P., Bonnotte B., Reny G., Entezam F., Lopez J., Bonnin A., Guy H. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother. 1993 Jan;31(1):161–169. doi: 10.1093/jac/31.1.161. [DOI] [PubMed] [Google Scholar]
  30. Caillot D., Chavanet P., Casasnovas O., Solary E., Zanetta G., Buisson M., Wagner O., Cuisenier B., Bonnin A., Camerlynck P. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis. 1992 Aug;11(8):722–725. doi: 10.1007/BF01989977. [DOI] [PubMed] [Google Scholar]
  31. Chabot G. G., Pazdur R., Valeriote F. A., Baker L. H. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci. 1989 Apr;78(4):307–310. doi: 10.1002/jps.2600780409. [DOI] [PubMed] [Google Scholar]
  32. Chavanet P., Charlier N., Brenet A., Goux A., Muggéo E., Caillot D., Casasnovas O., Kistermann J. P., Waldner A., Portier H. Emulsion de l'amphotéricine B dans l'Intralipide 20%: efficacité in vitro et in vivo. Pathol Biol (Paris) 1992 May;40(5):507–512. [PubMed] [Google Scholar]
  33. Clark J. M., Whitney R. R., Olsen S. J., George R. J., Swerdel M. R., Kunselman L., Bonner D. P. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother. 1991 Apr;35(4):615–621. doi: 10.1128/aac.35.4.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Clements J. S., Jr, Peacock J. E., Jr Amphotericin B revisited: reassessment of toxicity. Am J Med. 1990 May;88(5N):22N–27N. [PubMed] [Google Scholar]
  35. Clemons K. V., Stevens D. A. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother. 1991 Oct;35(10):2144–2146. doi: 10.1128/aac.35.10.2144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Clemons K. V., Stevens D. A. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother. 1991 Sep;35(9):1829–1833. doi: 10.1128/aac.35.9.1829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Clemons K. V., Stevens D. A. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J Antimicrob Chemother. 1992 Sep;30(3):353–363. doi: 10.1093/jac/30.3.353. [DOI] [PubMed] [Google Scholar]
  38. Clemons K. V., Stevens D. A. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrob Chemother. 1993 Sep;32(3):465–472. doi: 10.1093/jac/32.3.465. [DOI] [PubMed] [Google Scholar]
  39. Cohen B. E. A sequential mechanism for the formation of aqueous channels by amphotericin B in liposomes. The effect of sterols and phospholipid composition. Biochim Biophys Acta. 1992 Jul 8;1108(1):49–58. doi: 10.1016/0005-2736(92)90113-z. [DOI] [PubMed] [Google Scholar]
  40. Cohen B. E. Concentration- and time-dependence of amphotericin-B induced permeability changes across ergosterol-containing liposomes. Biochim Biophys Acta. 1986 May 9;857(1):117–122. doi: 10.1016/0005-2736(86)90104-5. [DOI] [PubMed] [Google Scholar]
  41. Collette N., Van der Auwera P., Meunier F., Lambert C., Sculier J. P., Coune A. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother. 1991 Apr;27(4):535–548. doi: 10.1093/jac/27.4.535. [DOI] [PubMed] [Google Scholar]
  42. Collette N., van der Auwera P., Lopez A. P., Heymans C., Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989 Mar;33(3):362–368. doi: 10.1128/aac.33.3.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Croft S. L., Davidson R. N., Thornton E. A. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):111–118. doi: 10.1093/jac/28.suppl_b.111. [DOI] [PubMed] [Google Scholar]
  44. Davidson R. N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G. B., Pempinello R., Scott S., Raimondi F., Cascio A. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med. 1994 Feb;87(2):75–81. [PubMed] [Google Scholar]
  45. Davis S. S., Washington C., West P., Illum L., Liversidge G., Sternson L., Kirsh R. Lipid emulsions as drug delivery systems. Ann N Y Acad Sci. 1987;507:75–88. doi: 10.1111/j.1749-6632.1987.tb45793.x. [DOI] [PubMed] [Google Scholar]
  46. Denning D. W. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):1–16. doi: 10.1093/jac/28.suppl_b.1. [DOI] [PubMed] [Google Scholar]
  47. Dromer F., Barbet J., Bolard J., Charreire J., Yeni P. Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes. Antimicrob Agents Chemother. 1990 Nov;34(11):2055–2060. doi: 10.1128/aac.34.11.2055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Dufourc E. J., Smith I. C., Jarrell H. C. Interaction of amphotericin B with membrane lipids as viewed by 2H-NMR. Biochim Biophys Acta. 1984 Dec 19;778(3):435–442. doi: 10.1016/0005-2736(84)90391-2. [DOI] [PubMed] [Google Scholar]
  49. Edmonds L. C., Davidson L., Bertino J. S., Jr Solubility and stability of amphotericin B in human serum. Ther Drug Monit. 1989;11(3):323–326. doi: 10.1097/00007691-198905000-00015. [DOI] [PubMed] [Google Scholar]
  50. Emminger W., Graninger W., Emminger-Schmidmeier W., Zoubek A., Pillwein K., Susani M., Wasserer A., Gadner H. Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer. Ann Hematol. 1994 Jan;68(1):27–31. doi: 10.1007/BF01695916. [DOI] [PubMed] [Google Scholar]
  51. Fielding R. M., Singer A. W., Wang L. H., Babbar S., Guo L. S. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother. 1992 Feb;36(2):299–307. doi: 10.1128/aac.36.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Fielding R. M., Smith P. C., Wang L. H., Porter J., Guo L. S. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother. 1991 Jun;35(6):1208–1213. doi: 10.1128/aac.35.6.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Fisher E. W., Toma A., Fisher P. H., Cheesman A. D. Rhinocerebral mucormycosis: use of liposomal amphotericin B. J Laryngol Otol. 1991 Jul;105(7):575–577. doi: 10.1017/s0022215100116652. [DOI] [PubMed] [Google Scholar]
  54. Francis P., Lee J. W., Hoffman A., Peter J., Francesconi A., Bacher J., Shelhamer J., Pizzo P. A., Walsh T. J. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis. 1994 Feb;169(2):356–368. doi: 10.1093/infdis/169.2.356. [DOI] [PubMed] [Google Scholar]
  55. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar]
  56. Gates C., Pinney R. J. Amphotericin B and its delivery by liposomal and lipid formulations. J Clin Pharm Ther. 1993 Jun;18(3):147–153. doi: 10.1111/j.1365-2710.1993.tb00605.x. [DOI] [PubMed] [Google Scholar]
  57. Gilbert B. E., Wyde P. R., Lopez-Berestein G., Wilson S. Z. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob Agents Chemother. 1994 Feb;38(2):356–359. doi: 10.1128/aac.38.2.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Gilbert B. E., Wyde P. R., Wilson S. Z. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother. 1992 Jul;36(7):1466–1471. doi: 10.1128/aac.36.7.1466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Gokhale P. C., Barapatre R. J., Advani S. H., Kshirsagar N. A., Pandya S. K. Pharmacokinetics and tolerance of liposomal amphotericin B in patients. J Antimicrob Chemother. 1993 Jul;32(1):133–139. doi: 10.1093/jac/32.1.133. [DOI] [PubMed] [Google Scholar]
  60. Gokhale P. C., Barapatre R. J., Advani S. H., Kshirsagar N. A., Pandya S. K. Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report. J Cancer Res Clin Oncol. 1993;119(10):569–571. doi: 10.1007/BF01372718. [DOI] [PubMed] [Google Scholar]
  61. Gondal J. A., Swartz R. P., Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989 Sep;33(9):1544–1548. doi: 10.1128/aac.33.9.1544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Grant C. W., Hamilton K. S., Hamilton K. D., Barber K. R. Physical biochemistry of a liposomal amphotericin B mixture used for patient treatment. Biochim Biophys Acta. 1989 Aug 21;984(1):11–20. doi: 10.1016/0005-2736(89)90336-2. [DOI] [PubMed] [Google Scholar]
  63. Graybill J. R., Bocanegra R. Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob Agents Chemother. 1995 Aug;39(8):1885–1887. doi: 10.1128/aac.39.8.1885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Graybill J. R., Craven P. C., Taylor R. L., Williams D. M., Magee W. E. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis. 1982 May;145(5):748–752. doi: 10.1093/infdis/145.2.748. [DOI] [PubMed] [Google Scholar]
  65. Graybill J. R. Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect. 1994 May;28 (Suppl 1):17–24. doi: 10.1016/s0163-4453(94)95926-9. [DOI] [PubMed] [Google Scholar]
  66. Gruda I., Gauthier E., Elberg S., Brajtburg J., Medoff G. Effects of the detergent sucrose monolaurate on binding of amphotericin B to sterols and its toxicity for cells. Biochem Biophys Res Commun. 1988 Aug 15;154(3):954–958. doi: 10.1016/0006-291x(88)90232-x. [DOI] [PubMed] [Google Scholar]
  67. Gruda I., Milette D., Brother M., Kobayashi G. S., Medoff G., Brajtburg J. Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose. Antimicrob Agents Chemother. 1991 Jan;35(1):24–28. doi: 10.1128/aac.35.1.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Hamilton K. S., Barber K. R., Davis J. H., Neil K., Grant C. W. Phase behaviour of amphotericin B multilamellar vesicles. Biochim Biophys Acta. 1991 Feb 25;1062(2):220–226. doi: 10.1016/0005-2736(91)90396-p. [DOI] [PubMed] [Google Scholar]
  69. Hanson L. H., Stevens D. A. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother. 1992 Feb;36(2):486–488. doi: 10.1128/aac.36.2.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Hay R. J. Liposomal amphotericin B, AmBisome. J Infect. 1994 May;28 (Suppl 1):35–43. doi: 10.1016/s0163-4453(94)95956-0. [DOI] [PubMed] [Google Scholar]
  71. Heymans C., Van der Auwera P., Sculier J. P., Coune A., Brassinne C., Laduron C., Hollaert C., Meunier F. In-vitro evaluation of the antifungal activity of amphotericin B entrapped into liposomes during storage for one year. J Antimicrob Chemother. 1990 Mar;25(3):361–366. doi: 10.1093/jac/25.3.361. [DOI] [PubMed] [Google Scholar]
  72. Hopfer R. L., Mehta R., Lopez-Berestein G. Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF. Antimicrob Agents Chemother. 1987 Dec;31(12):1978–1981. doi: 10.1128/aac.31.12.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Hopfer R. L., Mills K., Mehta R., Lopez-Berestein G., Fainstein V., Juliano R. L. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother. 1984 Mar;25(3):387–389. doi: 10.1128/aac.25.3.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Hospenthal D. R., Rogers A. L., Beneke E. S. Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob Agents Chemother. 1989 Jan;33(1):16–18. doi: 10.1128/aac.33.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Hospenthal D., Gretzinger K., Rogers A. Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to Candida albicans. J Med Microbiol. 1989 Nov;30(3):193–197. doi: 10.1099/00222615-30-3-193. [DOI] [PubMed] [Google Scholar]
  76. Hostetler J. S., Clemons K. V., Hanson L. H., Stevens D. A. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother. 1992 Dec;36(12):2656–2660. doi: 10.1128/aac.36.12.2656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Hughes C. E., Bennett R. L., Beggs W. H. Broth dilution testing of Candida albicans susceptibility to ketoconazole. Antimicrob Agents Chemother. 1987 Apr;31(4):643–646. doi: 10.1128/aac.31.4.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Janknegt R., de Marie S., Bakker-Woudenberg I. A., Crommelin D. J. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet. 1992 Oct;23(4):279–291. doi: 10.2165/00003088-199223040-00004. [DOI] [PubMed] [Google Scholar]
  79. Janoff A. S., Boni L. T., Popescu M. C., Minchey S. R., Cullis P. R., Madden T. D., Taraschi T., Gruner S. M., Shyamsunder E., Tate M. W. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6122–6126. doi: 10.1073/pnas.85.16.6122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Joly V., Bolard J., Saint-Julien L., Carbon C., Yeni P. Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations. Antimicrob Agents Chemother. 1992 Feb;36(2):262–266. doi: 10.1128/aac.36.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Joly V., Bolard J., Yeni P. In vitro models for studying toxicity of antifungal agents. Antimicrob Agents Chemother. 1992 Sep;36(9):1799–1804. doi: 10.1128/aac.36.9.1799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Joly V., Farinotti R., Saint-Julien L., Chéron M., Carbon C., Yeni P. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob Agents Chemother. 1994 Feb;38(2):177–183. doi: 10.1128/aac.38.2.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Joly V., Saint-Julien L., Carbon C., Yeni P. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture. J Pharmacol Exp Ther. 1990 Oct;255(1):17–22. [PubMed] [Google Scholar]
  84. Juliano R. L., Grant C. W., Barber K. R., Kalp M. A. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol. 1987 Jan;31(1):1–11. [PubMed] [Google Scholar]
  85. Jullien S., Brajtburg J., Bolard J. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations. Biochim Biophys Acta. 1990 Jan 15;1021(1):39–45. doi: 10.1016/0005-2736(90)90381-w. [DOI] [PubMed] [Google Scholar]
  86. Jullien S., Contrepois A., Sligh J. E., Domart Y., Yeni P., Brajtburg J., Medoff G., Bolard J. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids. Antimicrob Agents Chemother. 1989 Mar;33(3):345–349. doi: 10.1128/aac.33.3.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Jullien S., Vertut-Croquin A., Brajtburg J., Bolard J. Circular dichroism for the determination of amphotericin B binding to liposomes. Anal Biochem. 1988 Jul;172(1):197–202. doi: 10.1016/0003-2697(88)90432-0. [DOI] [PubMed] [Google Scholar]
  88. Kan V. L., Bennett J. E., Amantea M. A., Smolskis M. C., McManus E., Grasela D. M., Sherman J. W. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis. 1991 Aug;164(2):418–421. doi: 10.1093/infdis/164.2.418. [DOI] [PubMed] [Google Scholar]
  89. Karyotakis N. C., Anaissie E. J. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob Agents Chemother. 1994 Nov;38(11):2660–2662. doi: 10.1128/aac.38.11.2660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Kerridge D. Mode of action of clinically important antifungal drugs. Adv Microb Physiol. 1986;27:1–72. doi: 10.1016/s0065-2911(08)60303-3. [DOI] [PubMed] [Google Scholar]
  91. Kintzel P. E., Kennedy P. E. Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line. Am J Hosp Pharm. 1991 Feb;48(2):283–285. [PubMed] [Google Scholar]
  92. Kirsh R., Goldstein R., Tarloff J., Parris D., Hook J., Hanna N., Bugelski P., Poste G. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis. 1988 Nov;158(5):1065–1070. doi: 10.1093/infdis/158.5.1065. [DOI] [PubMed] [Google Scholar]
  93. Koldin M. H., Kobayashi G. S., Brajtburg J., Medoff G. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob Agents Chemother. 1985 Jul;28(1):144–145. doi: 10.1128/aac.28.1.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Kotler-Brajtburg J., Medoff G., Schlessinger D., Kobayashi G. S. Characterization of the binding of amphotericin B to Saccharomyces cerevisiae and relationship to the antifungal effects. Antimicrob Agents Chemother. 1974 Dec;6(6):770–776. doi: 10.1128/aac.6.6.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Krause H. J., Juliano R. L. Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures. Mol Pharmacol. 1988 Sep;34(3):286–297. [PubMed] [Google Scholar]
  96. Lamb K. A., Washington C., Davis S. S., Denyer S. P. Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers. J Pharm Pharmacol. 1991 Jul;43(7):522–524. doi: 10.1111/j.2042-7158.1991.tb03529.x. [DOI] [PubMed] [Google Scholar]
  97. Lambert P. A., Hammond S. M. Potassium fluxes, first indications of membrane damage in micro-organisms. Biochem Biophys Res Commun. 1973 Sep 18;54(2):796–799. doi: 10.1016/0006-291x(73)91494-0. [DOI] [PubMed] [Google Scholar]
  98. Lamy-Freund M. T., Ferreira V. F., Faljoni-Alário A., Schreier S. Effect of aggregation on the kinetics of autoxidation of the polyene antibiotic amphotericin B. J Pharm Sci. 1993 Feb;82(2):162–166. doi: 10.1002/jps.2600820209. [DOI] [PubMed] [Google Scholar]
  99. Lee J. W., Amantea M. A., Francis P. A., Navarro E. E., Bacher J., Pizzo P. A., Walsh T. J. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother. 1994 Apr;38(4):713–718. doi: 10.1128/aac.38.4.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Lee M. D., Hess M. M., Boucher B. A., Apple A. M. Stability of amphotericin B in 5% dextrose injection stored at 4 or 25 degrees C for 120 hours. Am J Hosp Pharm. 1994 Feb 1;51(3):394–396. [PubMed] [Google Scholar]
  101. Legrand P., Romero E. A., Cohen B. E., Bolard J. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother. 1992 Nov;36(11):2518–2522. doi: 10.1128/aac.36.11.2518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Legrand P., Vertut-Doi A., Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother. 1996 Mar;37(3):519–533. doi: 10.1093/jac/37.3.519. [DOI] [PubMed] [Google Scholar]
  103. Levy R. A., Ostlund R. E., Jr, Brajtburg J. The effects of amphotericin B on lipid metabolism in cultured human skin fibroblasts. In Vitro Cell Dev Biol. 1985 Jan;21(1):26–31. doi: 10.1007/BF02620910. [DOI] [PubMed] [Google Scholar]
  104. Lopez-Berestein G., Bodey G. P., Frankel L. S., Mehta K. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987 Feb;5(2):310–317. doi: 10.1200/JCO.1987.5.2.310. [DOI] [PubMed] [Google Scholar]
  105. Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
  106. Lopez-Berestein G., Hopfer R. L., Mehta R., Mehta K., Hersh E. M., Juliano R. L. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis. 1984 Aug;150(2):278–283. doi: 10.1093/infdis/150.2.278. [DOI] [PubMed] [Google Scholar]
  107. Lopez-Berestein G., Hopfer R. L., Mehta R., Mehta K., Hersh E. M., Juliano R. L. Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B. Antimicrob Agents Chemother. 1984 Mar;25(3):366–367. doi: 10.1128/aac.25.3.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Lopez-Berestein G. Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother. 1987 May;31(5):675–678. doi: 10.1128/aac.31.5.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Lopez-Berestein G., Mehta R., Hopfer R. L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E. M., Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May;147(5):939–945. doi: 10.1093/infdis/147.5.939. [DOI] [PubMed] [Google Scholar]
  110. Lopez-Berestein G., Mehta R., Hopfer R., Mehta K., Hersh E. M., Juliano R. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv. 1983;1(1):37–42. doi: 10.1089/cdd.1983.1.37. [DOI] [PubMed] [Google Scholar]
  111. Madden T. D., Janoff A. S., Cullis P. R. Incorporation of amphotericin B into large unilamellar vesicles composed of phosphatidylcholine and phosphatidylglycerol. Chem Phys Lipids. 1990 Feb;52(3-4):189–198. doi: 10.1016/0009-3084(90)90114-7. [DOI] [PubMed] [Google Scholar]
  112. Martin G. P., el-Hariri L. M., Marriott C. Bile salt- and lysophosphatidylcholine-induced membrane damage in human erythrocytes. J Pharm Pharmacol. 1992 Aug;44(8):646–650. doi: 10.1111/j.2042-7158.1992.tb05486.x. [DOI] [PubMed] [Google Scholar]
  113. Mehta R. T., McQueen T. J., Keyhani A., López-Berestein G. Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy. 1994 Jul-Aug;40(4):256–264. doi: 10.1159/000239202. [DOI] [PubMed] [Google Scholar]
  114. Mehta R. T., Mehta K., Lopez-Berestein G., Juliano R. L. Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect Immun. 1985 Feb;47(2):429–433. doi: 10.1128/iai.47.2.429-433.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Mehta R., Lopez-Berestein G., Hopfer R., Mills K., Juliano R. L. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta. 1984 Mar 14;770(2):230–234. doi: 10.1016/0005-2736(84)90135-4. [DOI] [PubMed] [Google Scholar]
  116. Meunier F. Alternative modalities of administering amphotericin B: current issues. J Infect. 1994 May;28 (Suppl 1):51–56. doi: 10.1016/s0163-4453(94)95986-2. [DOI] [PubMed] [Google Scholar]
  117. Meunier F., Sculier J. P., Coune A., Brassinne C., Heyman C., Laduron C., Collette N., Hollaert C., Bron D., Klastersky J. Amphotericin B encapsulated in liposomes administered to cancer patients. Ann N Y Acad Sci. 1988;544:598–610. doi: 10.1111/j.1749-6632.1988.tb40460.x. [DOI] [PubMed] [Google Scholar]
  118. Milhaud J., Hartmann M. A., Bolard J. Interaction of the polyene antibiotic amphotericin B with model membranes: differences between small and large unilamellar vesicles. Biochimie. 1989 Jan;71(1):49–56. doi: 10.1016/0300-9084(89)90130-2. [DOI] [PubMed] [Google Scholar]
  119. Mitrano F. P., Outman W. R., Baptista R. J., Palombo J. D. Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4 degrees C for 35 days. Am J Hosp Pharm. 1991 Dec;48(12):2635–2637. [PubMed] [Google Scholar]
  120. Mitsutake K., Kohno S., Miyazaki Y., Noda T., Miyazaki H., Miyazaki T., Kaku M., Koga H., Hara K. In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologia. 1994 Oct;128(1):13–17. doi: 10.1007/BF01104273. [DOI] [PubMed] [Google Scholar]
  121. Miyazaki T., Kohno S., Kaku M., Koga H., Yamaguchi K. Liposome-encapsulated amphotericin B in the treatment of experimental murine candidiasis. Tohoku J Exp Med. 1990 Aug;161(4):273–281. doi: 10.1620/tjem.161.273. [DOI] [PubMed] [Google Scholar]
  122. Moonis M., Ahmad I., Bachhawat B. K. Effect of elimination of phagocytic cells by liposomal dichloromethylene diphosphonate on aspergillosis virulence and toxicity of liposomal amphotericin B in mice. J Antimicrob Chemother. 1994 Mar;33(3):571–583. doi: 10.1093/jac/33.3.571. [DOI] [PubMed] [Google Scholar]
  123. Moreau P., Milpied N., Fayette N., Ramée J. F., Harousseau J. L. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother. 1992 Oct;30(4):535–541. doi: 10.1093/jac/30.4.535. [DOI] [PubMed] [Google Scholar]
  124. New R. R., Chance M. L., Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother. 1981 Nov;8(5):371–381. doi: 10.1093/jac/8.5.371. [DOI] [PubMed] [Google Scholar]
  125. Olsen S. J., Swerdel M. R., Blue B., Clark J. M., Bonner D. P. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol. 1991 Dec;43(12):831–835. doi: 10.1111/j.2042-7158.1991.tb03189.x. [DOI] [PubMed] [Google Scholar]
  126. Patterson T. F., Miniter P., Dijkstra J., Szoka F. C., Jr, Ryan J. L., Andriole V. T. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis. 1989 Apr;159(4):717–724. doi: 10.1093/infdis/159.4.717. [DOI] [PubMed] [Google Scholar]
  127. Payne N. I., Cosgrove R. F., Green A. P., Liu L. In-vivo studies of amphotericin B liposomes derived from proliposomes: effect of formulation on toxicity and tissue disposition of the drug in mice. J Pharm Pharmacol. 1987 Jan;39(1):24–28. doi: 10.1111/j.2042-7158.1987.tb07156.x. [DOI] [PubMed] [Google Scholar]
  128. Perfect J. R., Wright K. A. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother. 1994 Jan;33(1):73–81. doi: 10.1093/jac/33.1.73. [DOI] [PubMed] [Google Scholar]
  129. Perfect J. R., Wright K. A. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother. 1994 Jan;33(1):73–81. doi: 10.1093/jac/33.1.73. [DOI] [PubMed] [Google Scholar]
  130. Perkins W. R., Minchey S. R., Boni L. T., Swenson C. E., Popescu M. C., Pasternack R. F., Janoff A. S. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta. 1992 Jun 30;1107(2):271–282. doi: 10.1016/0005-2736(92)90414-h. [DOI] [PubMed] [Google Scholar]
  131. Pfaller M. A., Bale M., Buschelman B., Lancaster M., Espinel-Ingroff A., Rex J. H., Rinaldi M. G. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol. 1994 Jul;32(7):1650–1653. doi: 10.1128/jcm.32.7.1650-1653.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Pisarik L., Joly V., Jullien S., Carbon C., Yeni P. Reduction of free amphotericin B acute toxicity in mice after intravenous administration of empty liposomes. J Infect Dis. 1990 May;161(5):1042–1044. doi: 10.1093/infdis/161.5.1042. [DOI] [PubMed] [Google Scholar]
  133. Powderly W. G., Kobayashi G. S., Herzig G. P., Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988 May;84(5):826–832. doi: 10.1016/0002-9343(88)90059-9. [DOI] [PubMed] [Google Scholar]
  134. Proffitt R. T., Satorius A., Chiang S. M., Sullivan L., Adler-Moore J. P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):49–61. doi: 10.1093/jac/28.suppl_b.49. [DOI] [PubMed] [Google Scholar]
  135. Ralph E. D., Barber K. R., Grant C. W. Clinical experience with multilamellar liposomal amphotericin B in patients with proven and suspected fungal infections. Scand J Infect Dis. 1993;25(4):487–496. doi: 10.3109/00365549309008531. [DOI] [PubMed] [Google Scholar]
  136. Ralph E. D., Khazindar A. M., Barber K. R., Grant C. W. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob Agents Chemother. 1991 Jan;35(1):188–191. doi: 10.1128/aac.35.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Ramos H., Attias de Murciano A., Cohen B. E., Bolard J. The polyene antibiotic amphotericin B acts as a Ca2+ ionophore in sterol-containing liposomes. Biochim Biophys Acta. 1989 Jul 10;982(2):303–306. doi: 10.1016/0005-2736(89)90069-2. [DOI] [PubMed] [Google Scholar]
  138. Ramos H., Brajtburg J., Marquez V., Cohen B. E. Comparison of the leishmanicidal activity of fungizone, liposomal AmB and amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Drugs Exp Clin Res. 1995;21(6):211–216. [PubMed] [Google Scholar]
  139. Reuhl K. R., Vapiwala M., Ryzlak M. T., Schaffner C. P. Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats. Antimicrob Agents Chemother. 1993 Mar;37(3):419–428. doi: 10.1128/aac.37.3.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Rocheleau H., Saint-Germain G., Barwicz J., Gruda I., Thérien H. M. Modulation of amphotericin B activity by association with mannose ester. Immunopharmacol Immunotoxicol. 1994 Aug;16(3):419–436. doi: 10.3109/08923979409007102. [DOI] [PubMed] [Google Scholar]
  141. Saint-Julien L., Joly V., Seman M., Carbon C., Yeni P. Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses. Antimicrob Agents Chemother. 1992 Dec;36(12):2722–2728. doi: 10.1128/aac.36.12.2722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Sanders S. W., Buchi K. N., Goddard M. S., Lang J. K., Tolman K. G. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother. 1991 Jun;35(6):1029–1034. doi: 10.1128/aac.35.6.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Schindler J. J., Warren R. P., Allen S. D., Jackson M. K. Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice. Antimicrob Agents Chemother. 1993 Dec;37(12):2716–2721. doi: 10.1128/aac.37.12.2716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Schmitt H. J., Bernard E. M., Häuser M., Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother. 1988 Nov;32(11):1676–1679. doi: 10.1128/aac.32.11.1676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Souza L. C., Maranhão R. C., Schreier S., Campa A. In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J Antimicrob Chemother. 1993 Jul;32(1):123–132. doi: 10.1093/jac/32.1.123. [DOI] [PubMed] [Google Scholar]
  146. Stevens D. A. Overview of amphotericin B colloidal dispersion (amphocil). J Infect. 1994 May;28 (Suppl 1):45–49. doi: 10.1016/s0163-4453(94)95971-4. [DOI] [PubMed] [Google Scholar]
  147. Sullivan G. W., Carper H. T., Mandell G. L. Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone). Antimicrob Agents Chemother. 1992 Jan;36(1):39–45. doi: 10.1128/aac.36.1.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Surarit R., Shepherd M. G. The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans. J Med Vet Mycol. 1987 Dec;25(6):403–413. doi: 10.1080/02681218780000491. [DOI] [PubMed] [Google Scholar]
  149. Szoka F. C., Jr, Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1987 Mar;31(3):421–429. doi: 10.1128/aac.31.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Tancrède P., Barwicz J., Jutras S., Gruda I. The effect of surfactants on the aggregation state of amphotericin B. Biochim Biophys Acta. 1990 Dec 14;1030(2):289–295. doi: 10.1016/0005-2736(90)90305-8. [DOI] [PubMed] [Google Scholar]
  151. Tasset C., Preat V., Roland M. Formulations galéniques d'amphotéricine B. J Pharm Belg. 1992 Nov-Dec;47(6):523–536. [PubMed] [Google Scholar]
  152. Tasset C., Préat V., Roland M. The influence of Myrj 59 on the solubility, toxicity and activity of amphotericin B. J Pharm Pharmacol. 1991 May;43(5):297–302. doi: 10.1111/j.2042-7158.1991.tb06693.x. [DOI] [PubMed] [Google Scholar]
  153. Taylor A. W., Costello B. J., Hunter P. A., MacLachlan W. S., Shanks C. T. Synthesis and antifungal selectivity of new derivatives of amphotericin B modified at the C-13 position. J Antibiot (Tokyo) 1993 Mar;46(3):486–493. doi: 10.7164/antibiotics.46.486. [DOI] [PubMed] [Google Scholar]
  154. Taylor R. L., Williams D. M., Craven P. C., Graybill J. R., Drutz D. J., Magee W. E. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis. 1982 May;125(5):610–611. doi: 10.1164/arrd.1982.125.5.610. [DOI] [PubMed] [Google Scholar]
  155. Tollemar J., Duraj F., Ericzon B. G. Liposomal amphotericin B treatment in a 9-month-old liver recipient. Mycoses. 1990 May;33(5):251–252. doi: 10.1111/myc.1990.33.5.251. [DOI] [PubMed] [Google Scholar]
  156. Tremblay C., Barza M., Fiore C., Szoka F. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1984 Aug;26(2):170–173. doi: 10.1128/aac.26.2.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  157. Valero G., Graybill J. R. Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob Agents Chemother. 1995 Nov;39(11):2588–2590. doi: 10.1128/aac.39.11.2588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Vecchiarelli A., Verducci G., Perito S., Puccetti P., Marconi P., Bistoni F. Involvement of host macrophages in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. J Antibiot (Tokyo) 1986 Jun;39(6):846–855. doi: 10.7164/antibiotics.39.846. [DOI] [PubMed] [Google Scholar]
  159. Vertut-Croquin A., Bolard J., Gary-Bobo C. M. Enhancement of amphotericin B selectivity by antibiotic incorporation into gel state vesicles. A circular dichroism and permeability study. Biochem Biophys Res Commun. 1984 Nov 30;125(1):360–366. doi: 10.1016/s0006-291x(84)80376-9. [DOI] [PubMed] [Google Scholar]
  160. Vertut-Croquin A., Bolard J., Gary-Bobo C. M. Transfer of amphotericin B from gel state vesicles to mycoplasma cells: biphasic action on potassium transport and permeability. Antimicrob Agents Chemother. 1985 Aug;28(2):167–171. doi: 10.1128/aac.28.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Vertut-Doi A., Hannaert P., Bolard J. The polyene antibiotic amphotericin B inhibits the Na+/K+ pump of human erythrocytes. Biochem Biophys Res Commun. 1988 Dec 15;157(2):692–697. doi: 10.1016/s0006-291x(88)80305-x. [DOI] [PubMed] [Google Scholar]
  162. Vertut-Doï A., Ohnishi S. I., Bolard J. The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrob Agents Chemother. 1994 Oct;38(10):2373–2379. doi: 10.1128/aac.38.10.2373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Viviani M. A., Rizzardini G., Tortorano A. M., Fasan M., Capetti A., Roverselli A. M., Gringeri A., Suter F. Lipid-based amphotericin B in the treatment of cryptococcosis. Infection. 1994 Mar-Apr;22(2):137–142. doi: 10.1007/BF01739025. [DOI] [PubMed] [Google Scholar]
  164. Vyvoda O. S., Coleman R., Holdsworth G. Effects of different bile salts upon the composition and morphology of a liver plasma membrane preparation. Deoxycholate is more membrane damaging than cholate and its conjugates. Biochim Biophys Acta. 1977 Feb 14;465(1):68–76. doi: 10.1016/0005-2736(77)90356-x. [DOI] [PubMed] [Google Scholar]
  165. Wang L. H., Fielding R. M., Smith P. C., Guo L. S. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm Res. 1995 Feb;12(2):275–283. doi: 10.1023/a:1016243313027. [DOI] [PubMed] [Google Scholar]
  166. Wasan K. M., Brazeau G. A., Keyhani A., Hayman A. C., Lopez-Berestein G. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother. 1993 Feb;37(2):246–250. doi: 10.1128/aac.37.2.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Wasan K. M., Lopez-Berestein G. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res. 1993 Winter;24(4):395–401. [PubMed] [Google Scholar]
  168. Wasan K. M., Morton R. E., Rosenblum M. G., Lopez-Berestein G. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci. 1994 Jul;83(7):1006–1010. doi: 10.1002/jps.2600830716. [DOI] [PubMed] [Google Scholar]
  169. Wasan K. M., Vadiei K., Lopez-Berestein G., Luke D. R. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis. 1990 Mar;161(3):562–566. doi: 10.1093/infdis/161.3.562. [DOI] [PubMed] [Google Scholar]
  170. Washington C., Lance M., Davis S. S. Toxicity of amphotericin B emulsion formulations. J Antimicrob Chemother. 1993 May;31(5):806–808. doi: 10.1093/jac/31.5.806. [DOI] [PubMed] [Google Scholar]
  171. Yamaguchi H., Abe S., Tokuda Y. Immunomodulating activity of antifungal drugs. Ann N Y Acad Sci. 1993 Jun 23;685:447–457. doi: 10.1111/j.1749-6632.1993.tb35905.x. [DOI] [PubMed] [Google Scholar]
  172. de Marie S., Janknegt R., Bakker-Woudenberg I. A. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother. 1994 May;33(5):907–916. doi: 10.1093/jac/33.5.907. [DOI] [PubMed] [Google Scholar]
  173. van Etten E. W., ten Kate M. T., Stearne L. E., Bakker-Woudenberg I. A. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother. 1995 Sep;39(9):1954–1958. doi: 10.1128/aac.39.9.1954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. van Etten E. W., van den Heuvel-de Groot C., Bakker-Woudenberg I. A. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J Antimicrob Chemother. 1993 Nov;32(5):723–739. doi: 10.1093/jac/32.5.723. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES